Jennifer S. Haas, MD, MSPH
Articles
November 16th 2012
Active Pharmacovigilance and Healthcare Utilization
Jennifer S. Haas, MD, MSPH Elissa Klinger, SM Lucas Xavier Marinacci, BA Phyllis Brawarsky, MPH E. John Orav, PhD Gordon D. Schiff, MD David W. Bates, MD, MSc
This study highlights the potential value of innovative ways of collecting information about adverse drug events directly from patients.
May 15th 2011
Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Jennifer S. Haas, MD, MSPH Kathryn A. Phillips, PhD Su-Ying Liang, PhD Michael J. Hassett, MD, MPH Carol Keohane, BSN, RN Elena B. Elkin, PhD Joanne Armstrong, MD, MPH Michele Toscano, MS
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
